Travere Therapeutics, Inc. (TVTX) has secured full FDA approval for FILSPARI (sparsentan), marking it as the first FDA-approved treatment for focal segmental glomerulosclerosis (FSGS) in patients aged 8 and older without nephrotic syndrome. This approval addresses a significant unmet need, as patients previously relied on off-label treatments with inconsistent benefits and notable side effects. FILSPARI, which also has approval for IgA nephropathy, is designed to reduce proteinuria, a critical marker of kidney disease progression.
The approval is expected to expand FILSPARI’s market potential to approximately 30,000 patients in the U.S. alone, contributing to a broader market of over 100,000 individuals with FSGS and IgAN. The drug has already demonstrated strong commercial momentum, with U.S. net product sales reaching $322 million in 2025, a 144% increase year-over-year.
For market professionals, the key takeaway is that Travere’s approval of FILSPARI could further enhance its revenue trajectory, while the ongoing support program for patients may bolster adoption rates among nephrologists, potentially driving stock performance in the coming quarters.
Source: nasdaq.com